GSK
GSK Plc
Stock NYSE – Stock Market Prices, News & Analysis
GSK Plc is a British pharmaceutical multinational engaged in the creation and commercialization of vaccines, treatments for various diseases, and consumer healthcare products.
GSK Plc
GSK
GSK Plc is a British pharmaceutical multinational engaged in the creation and commercialization of vaccines, treatments for various diseases, and consumer healthcare products.
Price history of GSK Plc
Price history of GSK Plc
Performance & Momentum
GSK boosts immuno-respiratory pipeline with $2.2B buyout
GSK completed the $2.2 billion acquisition of RAPT Therapeutics, adding Ozureprubart to its portfolio. This move aims to strengthen its immunology and respiratory disease segments, key strategic areas for the company. Despite a modest recent share decline (-1.1% in one day, -3.4% over a week), management continues to invest heavily, supporting medium-term growth potential. However, the overall US vaccine market remains subdued, affecting certain sector players' momentum.
Strategic Analysis
GSK Plc • 2026
GSK Plc positions itself as a major player in the UK pharmaceutical sector, combining strong expertise in vaccines and respiratory-immunology treatments. Its strategy is based on innovation and the targeted expansion of its pipelines through strategic acquisitions in order to solidify its presence in high-growth segments.
Strengths
- Diversified portfolio integrating vaccines, treatments, and consumer health products
- Ongoing strengthening of the pipeline through significant investments in respiratory-immunology
- Strong position in a regulated global market with a high capacity for innovation
Weaknesses
- Dependence on strict regulations and delays in the approval of new drugs
Momentum
The stock shows very favorable momentum, supported by solid progress over recent periods, reflecting growing investor confidence in the growth strategy. The recent acquisition for $2.2 billion underscores enhanced dynamism in promising segments, which should stimulate medium-term development.
Similar stocks to GSK Plc
Recent News
GSK Plc
GSK to raise prices on 350 US drugs in 2026
2 months agoGlaxoSmithKline (GSK) plans price increases on about 350 drugs starting January 2026 in the US. Despite federal pressure to limit treatment costs, GSK intends to raise prices by an average of 4%, in line with a recent agreement with the US administration aimed at improving drug accessibility. This increase could boost GSK's margins in the short term, while navigating a regulatory environment sensitive to drug pricing.
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
